Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

GRI Bio, Inc. GRI NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
49/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

GRI Bio, Inc. (GRI) is a Biotechnology company in the Healthcare sector, currently trading at $2.47. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Valuation: GRI trades at a trailing Price-to-Earnings (P/E) of -0.1 (S&P 500 average ~25).

Net income is $12M (loss), growing at -104.6%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $71,000 against $6M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 3.25 (strong liquidity). Debt-to-assets is 0.8%. Total assets: $9M.

Analyst outlook: 2 / 2 analysts rate GRI as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

GRI SharesGrow Score Overview

61/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — GRI

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
GRI: +0%/yr revenue is, -104.6%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet GRI: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 3.25 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
GRI: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 2 / 2 analysts rate GRI as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range2.1-80.36
Volume50.19K
Avg Volume (30D)396.09K
Market Cap$221.89K
Beta (1Y)-1.24
Share Statistics
EPS (TTM)-121.80
Shares Outstanding$98.16K
IPO Date2023-04-24
Employees3
CEOW. Marc Hertz
Financial Highlights & Ratios
Gross Profit$-4K
EBITDA$-11.97M
Net Income$-11.96M
Operating Income$-11.98M
Total Cash$8.23M
Total Debt$71K
Net Debt$-8.16M
Total Assets$8.67M
Price / Earnings (P/E)-0
Analyst Forecast
Rating ConsensusBuy
Analysts Covering2
Buy 100% Hold 0% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS3622AW5029

Price Chart

Track all markets on TradingView
GRI
GRI Bio, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
2.10 52WK RANGE 80.36

People Also View

CELC
CELC
Celcuity Inc.
$123.47
+2.17%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.70
+1.63%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$18.23
+4.17%
 DSGN
DSGN
Design Therapeutics, Inc.
$12.75
+0.87%
 IKNA
IKNA
Ikena Oncology, Inc.
$17.16
+1,152.55%
 STTK
STTK
Shattuck Labs, Inc.
$7.17
+5.75%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
 PRLD
PRLD
Prelude Therapeutics Incorporated
$5.52
+25.45%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message